Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Genetically Engineered Cells (FSHCER T cells) for the Treatment of Recurrent Platinum-resistant or Platinum-refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Trial Status: active

This phase I trial tests the safety, side effects and best dose of autologous anti-FSHR CER-4-1BB/CD3zeta-expressing T-lymphocytes (FSHCER T cells) with or without conditioning chemotherapy in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent), has come back after platinum-based chemotherapy (platinum-resistant), or has progressed during platinum-based chemotherapy (platinum-refractory). T cells are infection fighting blood cells that can kill tumor cells. The T cells given in this study will come from the patient and will have a new gene put in them that makes them able to recognize FSHR, a protein on the surface of tumor cells. These FSHR-specific T cells may help the body's immune system identify and kill FSHR expressing tumor cells. Drugs used in chemotherapy, such as cyclophosphamide and fludarabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before FSHCER T cells helps kill cancer cells in the body and may help the FSHCER T cells last longer in the body.